In a nutshell This paper studied the use of pioglitazone (Actos) with imatinib (Gleevec) in patients with chronic myeloid leukemia (CML). The authors concluded that the addition of pioglitazone improved response. Some background Chronic myeloid leukemia is a cancer of the bone marrow, where there is an excess of...
Read More
In a nutshell This study examined the safety and effectiveness of CAR-T cell therapy, a new type of immunotherapy, for relapsed acute lymphoblastic leukemia (ALL). Authors reported high remission rates with CAR-T cell therapy, even for patients with several relapses or for whom stem cell transplantation had failed. Some background Chemotherapy is...
Read More
In a nutshell This study examined how adhering to imatinib (Gleevac) treatment for chronic myeloid leukemia (CML) affects response rates. Researchers reported superior treatment response rates among patients with high adherence to the treatment regime. They suggested that poor adherence may therefore contribute to poorer treatment outcomes. Some...
Read More
In a nutshell This study examined the effectiveness of bosutinib (Bosulif), a tyrosine kinase inhibitor (TKI), after previous treatment with multiple TKIs for chronic myeloid leukemia (CML). Researchers concluded that bosutinib was associated with good effectiveness for CML patients for whom previous TKIs have failed. Some background Targeted...
Read More
In a nutshell This study examined stem cell transplantation (SCT) in childhood acute myeloid leukemia (AML) patients who are not responding to other treatments. This study concluded that SCT was an effective treatment in many patients, but certain risk factors were associated with worse outcomes. Some background Between 5% and 23% of childhood AML...
Read More
In a nutshell This study reported treatment outcomes in children with one or more relapses of acute lymphoblastic leukemia (ALL). Authors reported complete remission (no sign of disease) rates of about 40% after the second relapse or later. Some background ALL is a type of cancer in which the bone marrow makes too many lymphoblasts (a type of...
Read More
In a nutshell This study compared the effectiveness of two types of tyrosine kinase inhibitors – imatinib (Gleevac) and nilotinib (Tasigna) – for chronic myeloid leukemia (CML). Researchers reported higher treatment response rates (on a molecular level) with nilotinib than with imatinib. No differences were observed between different doses...
Read More
In a nutshell This study looked at the safety and effectiveness of donor stem cell transplantation in chronic lymphocytic leukemia (CLL) patients who have not responded well to previous treatments. The authors concluded that stem cell transplants can lead to long-term minimal residual disease-free survival for up to one-half of patients. Some...
Read MoreIn a nutshell This study looked at the effectiveness and safety of high dose steroid treatment with methylprednisolone (Medrol) combined with rituximab (Rituxan) for late stage chronic lymphocytic leukemia (CLL). The authors concluded this combination of treatments is more effective than methylprednisolone treatment alone, but that there are serious...
Read MoreIn a nutshell This study examined the combination of rituximab (Rituxan) and idelalisib (Zydelig) for patients with relapsed chronic lymphocytic leukemia (CLL) and additional medical conditions. Researchers concluded that the combination of both treatments improved disease progression and survival when compared to rituximab alone. Some background...
Read More
